Cereset Research for Caregivers

Inclusion Criteria: * Participants must provide caregiving at least 10 hours per week. This includes all types of caregiving * participants must be willing to provide informed consent * participants must be able to comply with basic instructions * participants must be able to sit comfortably for up to 90 minutes, and attend up to three 60-minute intervention sessions each week during the 4-week intervention period * participants must self report experiencing symptoms of stress, anxiety, or insomnia and meet threshold scores on one or more self-report inventories of these symptoms (Insomnia Severity Index (ISI, ≥ 8), the Perceived Stress Index (PSS, ≥ 14), or the Generalized Anxiety Disorder 7-item (GAD-7, ≥ 5) scale) Exclusion criteria: * participants providing less than 10 hours a week of care to a person * participants who are unable or unwilling to attend intervention sessions during the planned study period * participants who are unable or unwilling to provide consent * participants who are not exhibiting symptoms of stress, anxiety or insomnia * participants with hearing impairment severe enough that they cannot perceive tones through ear buds * participants with known seizure disorder, or suicidal thoughts within the last 3 months * participants who respond positively to a question about risk for suicide within the last 3 months will be excluded and receive a behavioral health resource list * participants weighing more than 400 pounds (the weight limit of the chair used during intervention) * participants currently enrolled in another intervention study * prior use (past 3 years) of the technology being tested * prior use of neuromodulation, neurostimulation, deep brain stimulation, neurofeedback, biofeedback, alpha stim, Eye Movement Desensitization and Reprocessing (EMDR),or electroconvulsive therapy within the last month * Pace makers and beta blockers that affect the assessment of heart rate variability will also be exclusionary * participants taking Medications that may affect the assessment of heart rate variability (beta blockers.